8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          The purpose of this study was to investigate the population pharmacokinetics (PK) of cefuroxime in patients undergoing coronary artery bypass graft (CABG) surgery. In this observational pharmacokinetic study, multiple blood samples were collected over a 48-h interval of intravenous cefuroxime administration. The samples were analyzed by using a validated high-performance liquid chromatography (HPLC) method. Population pharmacokinetic models were developed using Monolix (version 4.4) software. Pharmacokinetic-pharmacodynamic (PD) simulations were performed to explore the ability of different dosage regimens to achieve the pharmacodynamic targets. A total of 468 blood samples from 78 patients were analyzed. The PK for cefuroxime were best described by a two-compartment model with between-subject variability on clearance, the volume of distribution of the central compartment, and the volume of distribution of the peripheral compartment. The clearance of cefuroxime was related to creatinine clearance (CL CR). Dosing simulations showed that standard dosing regimens of 1.5 g could achieve the PK-PD target of the percentage of the time that the free concentration is maintained above the MIC during a dosing interval ( fT MIC) of 65% for an MIC of 8 mg/liter in patients with a CL CR of 30, 60, or 90 ml/min, whereas this dosing regimen failed to achieve the PK-PD target in patients with a CL CR of ≥125 ml/min. In conclusion, administration of standard doses of 1.5 g three times daily provided adequate antibiotic prophylaxis in patients undergoing CABG surgery. Lower doses failed to achieve the PK-PD target. Patients with high CL CR values required either higher doses or shorter intervals of cefuroxime dosing. On the other hand, lower doses (1 g three times daily) produced adequate target attainment for patients with low CL CR values (≤30 ml/min).

          Related collections

          Author and article information

          Journal
          Antimicrob Agents Chemother
          Antimicrob. Agents Chemother
          aac
          aac
          AAC
          Antimicrobial Agents and Chemotherapy
          American Society for Microbiology (1752 N St., N.W., Washington, DC )
          0066-4804
          1098-6596
          22 January 2018
          27 March 2018
          April 2018
          : 62
          : 4
          : e02241-17
          Affiliations
          [a ]Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
          [b ]Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City, Riyadh, Saudi Arabia
          [c ]Cardiac Surgery Department, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
          [d ]Cardiac Anesthesia Department, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
          Author notes
          Address correspondence to Saeed A. Alqahtani, saeed@ 123456ksu.edu.sa .

          Citation Alqahtani SA, Alsultan AS, Alqattan HM, Eldemerdash A, Albacker TB. 2018. Population pharmacokinetic model-based evaluation of standard dosing regimens for cefuroxime used in coronary artery bypass graft surgery with cardiopulmonary bypass. Antimicrob Agents Chemother 62:e02241-17. https://doi.org/10.1128/AAC.02241-17.

          Article
          PMC5913949 PMC5913949 5913949 02241-17
          10.1128/AAC.02241-17
          5913949
          29358296
          b9608c04-9559-4432-932c-0bf7f49ae22b
          Copyright © 2018 American Society for Microbiology.

          All Rights Reserved.

          History
          : 30 October 2017
          : 2 December 2017
          : 9 January 2018
          Page count
          Figures: 3, Tables: 3, Equations: 0, References: 34, Pages: 9, Words: 5205
          Categories
          Experimental Therapeutics
          Custom metadata
          April 2018

          β-lactams,cefuroxime,CABG,Monte Carlo simulation,population PK,antibiotic prophylaxis,pharmacokinetics-pharmacodynamics

          Comments

          Comment on this article